Market Sentiment Around Loss-Making BioHarvest Sciences Inc. (NASDAQ:BHST)

We feel now is a pretty good time to analyse BioHarvest Sciences Inc.'s (NASDAQ:BHST) business as it appears the company may be on the cusp of a considerable accomplishment. BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. The company’s loss has recently broadened since it announced a US$11m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$11m, moving it further away from breakeven. Many investors are wondering about the rate at which BioHarvest Sciences will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Consensus from 4 of the American Personal Products analysts is that BioHarvest Sciences is on the verge of breakeven. They expect the company to post a final loss in 2027, before turning a profit of US$10m in 2028. The company is therefore projected to breakeven around 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 61% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for BioHarvest Sciences given that this is a high-level summary, but, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

See our latest analysis for BioHarvest Sciences

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 11% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of BioHarvest Sciences which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at BioHarvest Sciences, take a look at BioHarvest Sciences' company page on Simply Wall St. We've also compiled a list of relevant aspects you should further examine:

1. Valuation: What is BioHarvest Sciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BioHarvest Sciences is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BioHarvest Sciences’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.